Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Expenses: 2019-2025

Historic Operating Expenses for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to $201.3 million.

  • Avidity Biosciences' Operating Expenses rose 100.34% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.3 million, marking a year-over-year increase of 89.16%. This contributed to the annual value of $389.8 million for FY2024, which is 59.01% up from last year.
  • Latest data reveals that Avidity Biosciences reported Operating Expenses of $201.3 million as of Q3 2025, which was up 15.02% from $175.0 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Operating Expenses ranged from a high of $201.3 million in Q3 2025 and a low of $26.6 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $104.0 million, with a median of $84.7 million in 2024.
  • Data for Avidity Biosciences' Operating Expenses shows a peak YoY spiked of 253.77% (in 2021) over the last 5 years.
  • Avidity Biosciences' Operating Expenses (Quarterly) stood at $40.4 million in 2021, then spiked by 38.60% to $56.0 million in 2022, then grew by 23.11% to $68.9 million in 2023, then spiked by 79.82% to $124.0 million in 2024, then soared by 100.34% to $201.3 million in 2025.
  • Its Operating Expenses was $201.3 million in Q3 2025, compared to $175.0 million in Q2 2025 and $133.1 million in Q1 2025.